Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Inclusion Criteria:

Histologically or cytologically confirmed prostate adenocarcinoma in the very low or low or favorable intermediate risk risk stratification groups (i.e. Gleason Grade groups 1 and 2) who are eligible for and who select XRT as their cancer management method.
Ability to receive prostatic artery embolization within 6-12 weeks of definitive radiation therapy.
Ability to understand and the willingness to sign a written informed consent document
Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans
American Urologic Association (AUA) or International Prostate Symptom Score (IPSS) Score ≥ 15
Normal organ and marrow function as defined in protocol

Exclusion Criteria:

Patients with Gleason Grade Group 1 or 2 PCa who select active surveillance as their cancer management method.
Receiving androgen deprivation therapy (ADT)
Patients with unfavorable intermediate (Gleason Grade Group 3) or high risk localized PCa (Gleason Grade Groups 4 and 5)
Receiving any investigational agents for the explicit purpose of prostatic size reduction
Inability to receive prostatic artery embolization (PAE) within 6-12 weeks of definitive radiation therapy
Active urinary tract infection (UTI)
History of severe allergic reaction to intravenous contrast media (iodinated and gadolinium- based) or any agents used during the PAE; patient cannot be medicated against allergic reaction prior to PAE.
Active cystolithiasis or prostatitis
Inability to have multi-parametric magnetic resonance imaging (mpMRI)
Prior transurethral resection of the prostate (TURP) within 2 years
Prostate size greater than or equal to150 grams
Vulnerable subjects (e.g., inmates and developmentally delayed adults) who are subjects for whom the study may be unsafe or whose rights may be violated with enrollment.